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Intermolecular Hydrogen Transfer and Solubility 
Tuning in Multi-Component Molecular Crystals of 
the API Piroxicam 
Lynne H. Thomas,a Anneke R. Klapwijk,a,b Craig Walesa,c and Chick C. Wilsona*  
A series of twelve multi-component molecular crystals of the active pharmaceutical ingredient 
(API) piroxicam (PX) have been synthesised and their structures analysed with respect to their 
supramolecular motifs and degree of intermolecular hydrogen transfer observed on formation 
of the various complexes.  The multi-component crystals of PX formed with a series of basic 
N-heterocycles are contrasted with those formed with strong haloanilic acids, with PX found to 
adopt different ionisation states.  The effect of the formation of these multi-component 
molecular crystals on the physical property of solubility, often crucial in API formulation, has 
been investigated and these solubility determinations are compared with those of the parent PX 
material.  Enhanced solubility is evident in some of the multi-component crystals formed. 
 
Introduction 
Multi-component crystallisation – also referred to as co-
crystallisation – is the method of bringing together two or more 
different molecules into the same crystal lattice to form a 
molecular complex or salt1. Molecular complexes from co-
crystallisation experiments are seen as an increasingly useful 
tool in the preparation of solid forms of active pharmaceutical 
ingredients (APIs), with molecular complexes of 
pharmaceuticals not only having the potential to be patented as 
new materials2, but also for improving the physicochemical 
properties of an API without compromising the structural 
integrity3.  Piroxicam (PX) is a non-steroidal anti-inflammatory 
drug (NSAID) that has been extensively studied in the solid 
state4-11.  Presented here are further investigations of multi-
component molecular crystals of this important API, with 
particular regard to the crystal engineering potential and the 
potential modification of relevant physical properties of the 
multi-component crystals formed, with respect to those of the 
parent material.  In terms of the crystal engineering aspects, the 
aim is to identify robust synthons which may be utilised for 
future design of molecular complexes of piroxicam, while the 
particular physical property under investigation here is that of 
solubility, relevant to a wide range of APIs in seeking to 
develop their optimized formulation in manufacturing and 
processing of pharmaceutical products. 
In the solid state, piroxicam has previously been shown to exist 
in two ionisation states when not in its neutral form.  While 
pure piroxicam exists in the non-ionised form in the solid state, 
it has been shown that in polar solvents, such as acetonitrile 
which is commonly used in crystallisation experiments with 
piroxicam, the zwitterionic form is present in large 
quantities12,13.  The formation of the zwitterion, through 
intramolecular hydrogen-transfer, has been observed in solvates 
and multi-component molecular crystals of piroxicam14 in 
almost equal numbers to molecular complexes including neutral 
piroxicam.  On the other hand, intermolecular hydrogen transfer 
has been observed in only one piroxicam complex, with 
ethanolamine (1:1, pKa = 9.5), forming a salt with a piroxicam 
anion (PX¯)15.  There is an ongoing debate as to nomenclature 
adopted in the case of neutral or ionic molecular complexes in 
this area; for convenience all such cases are generally referred 
to as multi-component molecular crystals in this work, while 
the ionisation state is clearly indicated. 
The occurrence of such proton transfer is often rationalised by 
pKa matching16, and the pKa rule16-18, which includes the 
approximation that ∆pKa = pKa[base] – pKa[acid] ≥ 3 for salt 
formation16.  This presents an interesting dilemma in attempting 
to apply the pKa rule to predict intermolecular hydrogen 
transfer in a potentially zwitterionic material such as piroxicam.  
The hydroxyl group of piroxicam has a pKa of 5.46, while that 
of the pyridine nitrogen is 1.86 (conjugate acid).  The 
likelihood of proton transfer will be influenced, as expected, by 
the crystallisation solvent, but intramolecular hydrogen transfer 
is also influenced by the solvent and therefore pKa values may 
not be consistent as zwitterionic forms can exist.  In the case of 
the piroxicam ethanolamine salt, intermolecular hydrogen 
transfer is successfully predicted by application of the pKa rule 
for hydrogen transfer15.  However, in general the tendency of 
piroxicam to adopt the zwitterionic tautomer when co-
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crystallised with weak acids must be taken into consideration 
when trying to predict hydrogen transfer. 
 
Figure 1. The different possible configurations  for  the piroxicam  (PX) molecule.  
Top  left, neutral PX with  an  intramolecular OH∙∙∙O hydrogen bond.    Top  right, 
zwitterionic  form  of  PX  with  a  significant  conformational  change  and  two 
intramolecular NH∙∙∙O hydrogen bonds.   Bottom  left, positively charged PX with 
an  intramolecular O‐H∙∙∙O  hydrogen  bond  and  both N  atoms  protonated;  the 
conformation  of  this  molecule  is  the  same  as  for  neutral  PX.    Bottom  right, 
negatively charged PX has a conformation similar to the zwitterionic form with a 
single intramolecular N‐H∙∙∙O hydrogen bond but with the pyridine ring rotated. 
In the present work, intermolecular proton transfer from 
piroxicam is investigated in the formation of a series of multi-
component molecular crystals.  In the first approach, nitrogen 
heterocycles (NHCs) of varying basicity are co-crystallised 
with piroxicam to investigate the occurrence of hydrogen 
transfer from the piroxicam molecule to the basic nitrogen of 
the heterocycle and examine the effect of the competition of 
intramolecular hydrogen-transfer.  In addition, the occurrence 
of the zwitterionic tautomer of piroxicam and the conditions 
which give rise to its formation in the solid state are 
investigated. 
In addition to using basic NHCs, a series of multi-component 
molecular crystals formed when piroxicam is co-crystallised 
with the strong organic acids, chloranilic and bromanilic acid 
are reported.  This is driven by the possibility of inducing 
protonation of the PX pyridine ring to form molecular salts in 
which piroxicam would be found in cationic form (PX+). 
An important target physical property in the study of molecular 
complexes of APIs is that of enhanced solubility (and hence 
potential delivery and bioavailability of the API).  This property 
is also investigated here, by comparing solubilities of the parent 
API piroxicam, for which some previous literature 
determinations are avaialble19,20, with those of the multi-
component crystals formed in this study. 
Experimental 
Eight multi-component molecular crystals of PX with N-
heterocyclic co-formers, and four with the strong chloro and 
bromo haloanilic acids were synthesised by multi-component 
evaporative crystallisation from 1:1 stoichiometric solutions of 
component starting materials, with either methanol or 
acetonitrile (ACN) as solvent.  The crystal structures were 
determined by single crystal X-ray diffraction† and include both 
solvated and polymorphic forms; the materials synthesized and 
studied are summarised in Table 1.   
In the cases of PX crystallization with imidazole and chloranilic 
acid, the product formed was found to vary with choice of 
solvent or crystallisation temperature.  For the PX imidazole 
system different solvates were formed through crystallisation 
from methanol (1) and also for the pair of materials crystallised 
from ACN at RT (2) and 50°C (3), while for PX with 
chloranilic acid, crystallisation from ACN at RT produced one 
polymorph (form I; 9), crystallisation at 40°C produced 
polymorphic form II (10), while crystallisation at 50°C 
produced a solvate (11).  This variation illustrates the 
sensitivity of molecular complex formation to the 
crystallisation conditions used. 
Single-crystal X-ray diffraction data were collected on 1-12 
using either a Bruker Apex II (1, 2, 4-6, 9-12) or a Bruker-
Nonius Kappa CCD (3, 7) diffractometer equipped with 
graphite monochromated Mo-Kα radiation (λ = 0.71073 Å), 
with the exception of those for 8.  The existence only of very 
small, weakly scattering, crystals led to data being collected for 
8 on the I19 beamline at the Diamond Light Source, Harwell, 
UK, using an incident radiation of wavelength 0.6889 Å; in 
spite of the use of synchrotron radiation, the quality of data for 
8 was rather poor.  All data were collected at 100K. All 
structures were solved by direct methods using SHELXS-9721 
and refined using SHELXL-9721 both within the WinGX 
program suite.22  All non-hydrogen atoms were refined 
anisotropically.  Treatment of the hydrogen atoms varied 
between the complexes studied, combining location of H atoms 
in difference Fourier maps, as detailed in the ESI.  Complexes 3 
and 6 showed evidence of disorder, which was modelled during 
the refinement, while the refinement of 8 was of rather poor 
quality and required the use of constraints due to the limited 
data available (see ESI). 
Solubilities of starting material (PX form I) and a selection of 
product multi-component crystals (1, 2, 4 9, 10) for which 
significant quantities of powdered samples could be prepared, 
were obtained using the Crystal16 parallel crystalliser from 
Avantium Technologies BV using turbidity probes on 1mL 
samples. Preliminary measurements of solubility were made in 
one or both of the solvents methanol and ethanol; attempts to 
measure in water were unsuccessful as on contact with water 
the complexes appeared to dissociate, with visual evidence 
(colour) that the co-former dissolved in the water and PXRD 
studies indicating the PX formed its monohydrate form as a 
residue on the surface of the water.  Vials were cycled through 
various temperature ranges between 5oC and 75 oC using a 
temperature ramp rate of 0.5 oC min-1, with bottom stirring at 
850rpm using standard magnetic stirrer bars. Data were 
analysed using CrystalClear software version 1.0.1.614 
supplied by Avantium Technologies BV.  These turbidity 
measurements of solubility of PX in the multi-component 
crystals studied are preliminary; for API targets, more detailed 
studies would focus on solubility in water, which are initially 
difficult in this case as noted above.  It should also be noted, 
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however, that for many molecular materials other than APIs, 
solubility in common solvents such as the simple alcohols is 
highly relevant and significant for function, and solubility 
measurements in media other than water are commonly 
employed in the development of new solid forms23. 
 
Table 1. Summary of multi-component molecular crystals including crystallization conditions and ionization state of the 
piroxicam molecule. 
Complex Co-former Solvent Crystallisation 
Temperature (°C) 
Product complex 
(1) Imidazole (IM) Methanol RT PX– IM+ hemihydrate (2:2 :1) 
(2) Imidazole (IM) Acetonitrile RT PX– IM+ ACN solvate (1:1:1) 
(3) Imidazole (IM) Acetonitrile 50 PX– IM+ ACN solvate (4:4:1) 
(4) 2-Methylimidazole (MIM) Acetonitrile RT/40/50 PX– MIM+ (1:1) 
(5) Benzimidazole (BZ) Acetonitrile 50 PX– BZ+ (1:1) 
(6) 1,2,4–Triazole (TA) Acetonitrile 40/50 PXZ (zwitterionic) TA (1:1) 
(7) Benzotriazole (BT) Acetonitrile RT/40 PXZ BT (1:1) 
(8) Pyrazine*(PZ) Acetonitrile 50 PXZ PZ (2:1) 
(9) Chloranilic acid (CA) Acetonitrile RT PX+ CA– (1:1) form I 
(10) Chloranilic acid (CA) Acetonitrile 40 PX+ CA– (1:1) form II 
(11) Chloranilic acid (CA) Acetonitrile 50 PX+ CA2– ACN solvate (2: 1: 2) 
(12) Bromanilic acid (BA) Acetonitrile RT/40/50 PX+ BA– (1:1) 
* Production of the PXZ:PZ complex was found to result only from a small minority of the preparations set up with these starting materials, and in small yield 
overall.  In addition, the resulting single crystals were small, and data were collected using synchrotron radiation.
Results and Discussion 
Piroxicam Conformation 
The protonation state of the piroxicam molecule can clearly be 
inferred not just from the identification of hydrogen atoms in 
Fourier difference maps, but also by the conformation of the 
molecule itself (Figure 1).  A significant molecular 
rearrangement accompanies the conversion of the neutral 
piroxicam molecule to its zwitterionic form.9  In the neutral 
piroxicam molecule, an intramolecular OH···O hydrogen bond 
is formed.  On conversion to the zwitterionic form, this 
hydrogen atom is transferred to the N atom of the pyridine ring 
and instead two NH···O charge assisted intramolecular 
hydrogen bonds are formed.  When the piroxicam molecule is 
protonated (PX+), both N atoms and the hydroxyl group O atom 
are protonated; the molecule in this case shows a preference for 
an intramolecular OH···O hydrogen bond and overall the 
molecule adopts a similar conformation to the neutral molecule 
(9-12; Figure 1, bottom left).  In contrast, the deprotonated 
piroxicam molecule (PX-) is always deprotonated at the 
hydroxyl group and thus adopts a configuration similar to the 
zwitterionic form, this time with only a single intramolecular 
NH···O hydrogen bond and therefore the pyridine ring is rotated 
when compared to the zwitterionic form (1-5; Figure 1, bottom 
right).  The piroxicam molecule therefore modifies its 
conformation in order to maximise the number of 
intramolecular hydrogen bonds in every case. 
Multi-component Molecular Crystals of Piroxicam with N-
heterocycles 
Of the eight PX complexes (for convenience, the shorthand 
“complexes” is adopted as a shorthand nomenclature for the 
term multi-component molecular crystals in some of the 
discussion below) with NHCs, transfer of the PX hydroxyl 
hydrogen to the NHC to form the deprotonated PX¯ occurs in 
five (1-5).  Three of these are solvated complexes with 
imidazole (IM), which all feature protonation of the IM.  The 
other three complexes (6-8) feature intramolecular hydrogen 
transfer within the PX molecule and form zwitterionic 
piroxicam (PXZ).  Hydrogen transfer is a consistent feature in 
these multi-component molecular crystals, with none 
containing the non-ionised form of piroxicam (PXN).  The 
conformation of the PX molecules is thus similar in all of the 
complexes with NHCs.  
All PX¯ complexes feature chains of alternating PX¯ and NHC, 
with an ABAB arrangement.  They also exhibit similar 
hydrogen bonding synthons, although with some noticeable 
differences.  Complexes 2-5 feature NHC molecules 
sandwiched between two PX¯ molecules and linked by 
NH···O=C hydrogen bonds to the PX¯ amide oxygen and 
NH···O¯ hydrogen bonds to the PX¯ enolate oxygen (Figure 2; 
geometrical parameters of hydrogen bonds are given in the 
ESI).  Complex 1 contrasts to these as neither of the two 
independent IM+ molecules follow this hydrogen bonding 
pattern despite also having an ABAB arrangement (Figure 3).  
Instead, one chain features hydrogen bonds from the IM+ NH 
groups to the PX¯ pyridine nitrogen and enolate oxygen, and 
the other chain has both NH groups hydrogen bonding to the 
PX¯ amide oxygen atoms.  One enolate oxygen atom of PX¯ is 
therefore not hydrogen bonded to the IM+ NH groups and 
instead forms a hydrogen bond to the IM+ CH in the 4/5 
position.  Other IM+ CH groups in the 4 and 5 positions in the 
structure form hydrogen bonds with either the PX¯ pyridine 
nitrogen or a sulfonyl oxygen atom. 
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Figure  2.  Hydrogen  bonding  in  the  ABAB  chains  in  complex  5  (the  dashes  ‘ 
indicate  a  symmetry  independent molecule or  interaction  e.g. A  and A’).    The 
same hydrogen bonding pattern  is  found  in 2‐4.   Hydrogen bonds denoted by 
letters, in this and subsequent figures, are fully specified in the ESI. 
 
Figure  3. Hydrogen bonding  in  the  chains of PXˉ  and  IM+  in  complex 1  (those 
marked with  ‘  indicate a  symmetry  independent molecule or  interaction e.g. A 
and A’).  One IM+ molecule forms both NH∙∙∙N and NH∙∙∙O hydrogen bonds (blue 
dashed  lines  from  B)  and  the  other  forms  two  NH∙∙∙O  hydrogen  bonds  (blue 
dashed  lines from B’).   Weaker hydrogen bonds  involving CH donors are shown 
as red dashed lines. 
Weak hydrogen bonds are also seen in the other PX¯ structures, 
with CH···N interactions occurring in the imidazole acetonitrile 
solvate complexes 2 and 3 (d and d’ in Figure 6 below), as well 
as with the analogous CH groups in the 5/8 positions of BZ+ in 
5 (d and d’ in Figure 2).  Complex 4 does not have this 
interaction due to the alternate PX¯ molecules lying head to 
head rather than head to tail which makes the pyridine nitrogen 
unavailable for hydrogen bonding to the MIM+ CH groups 
(Figure 4).  A CH···O=S interaction is present in complexes 4 
and 5 (5/8 position; e and e’ in Figure 2) but not in either of the 
imidazole ACN solvates 2 and 3.  In 2, the lack of interaction is 
compensated for by a CH hydrogen bond forming to the ACN 
nitrogen, with the ACN methyl group then forming a CH···O=S 
hydrogen bond to the PX¯ molecule (Figure 5).  A similar 
CH···N hydrogen bond to the ACN is formed in 3, although no 
CH···O=S interaction is formed between the ACN and PX¯ as 
the ACN methyl group points away from the sulfonyl oxygen 
(Figure 6). 
 
Figure 4. NH∙∙∙Oˉ and NH∙∙∙O hydrogen bonds  (blue dashed  lines) between PXˉ 
and  2MIM+  and  the  weak  CH∙∙∙O  hydrogen  bond  (red  dashed  line),  in  the 
molecular salt complex 4.  The molecules lie head to head and this arrangement 
means that there are no CH∙∙∙N weak hydrogen bonds formed. 
 
Figure 5. Weak hydrogen bonds involving the ACN molecule in 2. (a) Weak CH∙∙∙O 
and  CH∙∙∙N  hydrogen  bonds  linking  ACN  molecules  into  the  chains  and  weak 
CH∙∙∙N hydrogen bonds resulting in ACN dimers. (b) Weak CH∙∙∙O hydrogen bond 
between the ACN molecule and the PXˉ molecule in the chain below. 
It is worthy of note that despite the similarity in hydrogen 
bonding arrangements between the IM+ complexes 1-3 and 
those of MIM+ (4) and BZ+ (5), no non-solvated multi-
component molecular crystals of PX and IM could be isolated, 
with instead two ACN solvates and a hydrate produced from 
varying the conditions.  This is likely due to the small size of 
IM compared with BZ and MIM, which both have bulky groups 
attached to the imidazole group.  To compensate for the void 
that would be left and to ensure efficient packing in the absence 
of these groups, a solvent molecule is incorporated into the 
PX¯:IM+ complexes.  This is reflected in the relative positions 
of the H2O and ACN molecules in 1-3, as the H2O molecule is 
hydrogen bonded to the CH group in the 2-position and the 
ACN molecules form hydrogen bonds to the CH in the 4/5 
position.  The solvent molecules therefore occupy equivalent 
positions to that adopted by methyl group and benzene ring in 
the complexes containing 2MIM (4) and BZ (5), respectively. 
In the three complexes featuring the zwitterionic PXZ with 
NHCs (6-8), the PXZ molecules dimerise, consistent with 
previously reported PXZ complexes9.  With the exception of 
the pyridinium nitrogen which is involved in hydrogen bonding 
to form the PXZ dimer, consistent hydrogen bonding is 
observed between the strongest N-heterocycle donors and the 
strongest free PXZ acceptors in all cases (Figures 7 and 8).  In 6 
and 7, NH···O¯ hydrogen bonds are formed between the TA/BT 
NH and the enolate oxygen (d in Figures 7 and 8).  The PZ CH 
also forms hydrogen bonds to the enolate O¯ (8).  In all 
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complexes a hydrogen bond is also formed from the same CH 
group of the PX¯ pyridine ring to a nitrogen atom of the 
heterocycles (e in Figures 7 and 8). 
 
 
Figure 6. Hydrogen bonding in the symmetry independent chains of PXˉ and IM+ 
molecules in 3. 
The PXZ:PZ complex 8 is unusual as the only hydrogen bonds 
between PZ and PXZ molecules involve CH donors, as this is 
the only possible PZ donor and the pyridinium nitrogen is 
unavailable due to dimerisation of PXZ molecules.  The fact 
that no conventional hydrogen bonds occur between the 
molecules may explain why crystallisation of this complex 
occurs so rarely and in such small quantities.  As PZ is 
symmetrical, the same interactions are formed on both sides of 
the molecule and it therefore forms chains with a BAABAAB 
configuration, with the PXZ dimers sandwiched by two PZ 
molecules and resulting in a 2:1 (PXZ:PZ) complex. 
In the PXZ:TA complex (6), disorder of the TA molecule 
means it can effectively form the same interactions on both 
sides (therefore it shows no preference for each orientation; the 
disorder is 50:50 over an inversion centre for the two 
independent TA molecules) and therefore also forms a 2:1 
complex of BAABAAB chains (Figure 7).  The small size of 
the molecule allows it to occupy two possible positions without 
major disruption of the crystal packing.  The PXZ:BT complex 
(7), however, forms a 1:1 complex with tetramers of 
BZT:PXZ:PXZ:BZT (BAAB; Figure 8, analogous to the 
common tetramer found in PXZ complexes with benzoic acids9.  
Chains are not formed as there is no symmetry in the BT 
molecule and only one sufficiently strong donor to form 
hydrogen bonds to the enolate O¯. 
 
Figure 7. (a) The hydrogen bonding between TA molecules and PXZ molecules in 
6,  with  (b)  showing  the  same  interactions  formed  in  reverse  when  the  TA 
molecule is in its second orientation (50:50 orientational disorder). 
 
Figure 8. Hydrogen bonding in the PXZ:BT complex, 7, forming a BAAB tetramer. 
Multi-component Molecular Crystals of Piroxicam with Strong 
Acids: Chloranilic Acid and Bromanilic Acid 
All multi-component molecular crystals of PX with CA and BA 
resulted in intermolecular hydrogen transfer from the CA/BA to 
the PX pyridine ring, forming the protonated PX+; the first time 
this ionic form of PX has been isolated in the solid state.  It 
adopts the same conformation as is seen in the non-ionised 
form of PX, with a short strong intramolecular OH···O 
hydrogen bond.  The CA/BA molecules are strong acids with 
two acidic OH groups; it is therefore possible to form both the 
singly charged anion and the doubly charged anion depending 
on the stoichiometry of the two components in a molecular 
complex.  In all these multi-component molecular crystals the 
strongest donor/strongest acceptor rule is satisfied, with charge-
assisted hydrogen bonds formed between the protonated 
pyridine nitrogen of PX+ and the deprotonated oxygen of CA¯ 
(or CA2¯). 
The polymorphic PX+:CA¯ forms I (9) and II (10) both 
crystallise in a 1:1 ratio, under different conditions but both 
from acetonitrile as the solvent (form I room temperature; form 
II 40°C).  Whilst bifurcated hydrogen bonds again form 
between the NH+ group of PX+ and the deprotonated part of 
CA-, there is a significant change in orientation of the CA¯ 
relative to the PX+ molecule between the two forms.  The two 
components (PX+ and CA¯) are more co-planar in form I (9) 
(rotation of ~20.9° between the plane of the PX+ pyridine ring 
and the plane of the CA¯ six-membered ring) and twisted by 
~81.4° in form II (10) (Figure 9).  This results in significantly 
different crystal packing (Figure 10).  In form I, homodimers of 
CA- are formed through the remaining OH group to form 
hydrogen bonded rings; these form isolated ABBA synthons 
with two CA- molecules sandwiched by PX+ molecules (Figure 
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10, top). In form II, the hydroxyl group forms an intermolecular 
hydrogen bond to a sulfonyl O atom on a PX+ molecule; these 
then assemble into hydrogen bonded chains in an ABAB 
arrangement contrasting to form I (Figure 10, bottom).   
 
Figure  9.  Relative  arrangements  of  the  PX+  (blue)  and  CAˉ  (red) molecules  in 
polymorphs  9  (a)  and  10  (b),  viewed  along  the  pyridine  ring  plane.    The  CAˉ 
molecule is significantly twisted in form 2 (10) and more co‐planar in form 1 (9). 
 
Figure 10. Tetrameric ABBA unit formed between the PX and CA molecules in the 
PX+:CA form I (9; top), contrasted with the arrangement in form II (10; bottom), 
in which  the CA molecules no  longer dimerise  through their OH group  (bottom 
left),  instead  the  latter  form  moderately  strong  OH∙∙∙O  interactions  with  the 
sulfonyl  oxygen  of  another  PX+  molecule  (orange  dashed  lines,  bottom)  and 
assemble  into  chains    through  bifurcated  hydrogen  bonds  (pink  dashed  lines, 
bottom).  Chloranilic acid in blue, piroxicam in green.. 
There are also halogen interactions involving the Cl atom. In 
form I, there are two C-H···Cl weak hydrogen bonds from 
aromatic CH groups on PX+ molecules and a Cl···O interaction 
with a sulfonyl O atom; in form II, there is only one interaction 
per Cl atom, one C-H···Cl weak hydrogen bond from a methyl 
group on a PX+ molecule and a Cl···π interaction to the fused 
benzene ring of a second PX+ molecule.  Since it is formed at a 
higher temperature of crystallisation and has lower density, 
form II is assumed to be the kinetic product.    
Increasing the crystallisation temperature again to 50°C 
resulted in the ACN solvate complex 11, with double 
deprotonation of the CA molecule and a 2:1 relative 
stoichiometry of PZ+:CA2- (Figure 11); this creates an ABA 
type supramolecular arrangement.  Deprotonation of both OH 
groups of the CA molecule is somewhat expected due to the 
decrease in pKa associated with increasing temperature but the 
fact that the relative orientation of the PX and CA components 
is more similar to that of the low temperature polymorphic form 
9 is not necessarily what would be expected as one might 
expect the product to be more similar to the kinetic form II than 
the thermodynamic form I; they are, however, not directly 
comparable due to the different ionization states of the CA. 
The PX+:BA¯ complex (12) is isostructural to the PX+:CA¯ 
form II complex, while it might be expected to be isostructural 
to the more thermodynamically stable form I.  Unlike the 
PX:CA complexes, only a single PX+:BA¯ phase was produced 
regardless of the temperature at which the crystallisation was 
carried out.   
 
Figure 11. Hydrogen bonding between CA2¯ and PX+ molecules forming the ABA 
motif in 11. 
Hydrogen Transfer and pKa – the complications of Zwitterionic 
forms 
Five of the eight multi-component molecular crystals of PX 
with N-heterocycles feature hydrogen transfer from the PX 
molecule to the basic nitrogen of the N-heterocycle; these 
represent the three most basic co-formers, all three IM 
complexes (1-3), the MIM complex (4) and the BZ complex 
(5). The ΔpKa values sit in the ΔpKa continuum region (see 
Table 2) and the value for benzimidazole is very close to zero 
and so proton transfer might not be expected.  However, the 
pKa values will have been determined in water and it may be 
that in acetonitrile, a greater proportion of molecules are in the 
zwitterionic form and a pKa value for this would be more 
realistic; this would be consistent with the structural picture 
where the PX- molecules adopt a conformation most similar to 
the zwitterionic form of PX.  The remaining three co-formers 
are poorly basic and resulted in multi-component molecular 
crystals with the zwitterionic PX tautomer (6-8).  The ΔpKa 
values show that the TA, BZ and PZ complexes would not be 
expected to result in intermolecular hydrogen transfer as they 
are all negative or very small; the pKa values for these co-
formers are consistent with the pKa boundaries suggested by 
Wales et al9 (all over 4) for a preference for the zwitterionic 
form.  The ΔpKa values (where PX acts as the conjugate base) 
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for the CA and BA complexes fall in the continuum region, but 
again, there may be differences dependent on whether the 
piroxicam molecule is in its neutral or zwitterionic forms in the 
solution. With systems in which zwitterionic forms are 
possible, the application of the simple ΔpKa rule is likely to be 
less reliable than in other cases.  
 
Table 2.  The ΔpKa values for piroxicam and co-molecules. 
Co-former pKa of 
co-
former 
PX 
Form 
ΔpKa OH 
(pKa = 
5.46)  
ΔpKa N+-H 
(pKa = 1.86) 
Bases 
Imidazole 6.99 PXˉ 1.53 ‐ 
2-methylimidazole 7.88 PXˉ 2.42 ‐ 
Benzimidazole 5.53 PXˉ 0.07 ‐ 
1,2,4-triazole 2.27 PXZ ‐3.19 ‐ 
Benzotriazole 1.60 PXZ ‐3.86 ‐ 
Pyrazine 0.65 PXZ ‐4.48 ‐ 
Acids    
Chloranilic Acid 0.76 PX+ - 1.1 
Bromanilic Acid 0.7 PX+ ‐ 1.16 
Solubility of Multi-component Molecular Crystals of PX  
The solubilities of the parent API piroxicam and of the w/w PX 
component of a series of the multi-component molecular 
crystals discussed above can be compared, to indicate whether 
formation of the multi-component crystal is found to increase 
or decrease the solubility of PX, a physical property vital for 
the potential delivery and bioavailability of such APIs.  The 
solubility curves of PX (form I) in methanol and ethanol were 
determined, with values determined for the latter found to be 
consistent with previous literature reports of PX solubility19,20.  
The curves are similar in shape, with PX less soluble in ethanol 
throughout the temperature range (Figure 12).  It should be 
noted that in the present study, no attempt has been made fully 
to characterise the degree of dissociation of the multi-
component crystal into its individual components in solution; 
this will be pursued in future work using in situ process 
analytical tools. 
 
Figure 12. PX solubility curve in methanol (top) and ethanol (bottom). 
Enhancement of the solubility is found for most of the multi-
component molecular crystals of PX measured to date, for 
example for 1 in methanol (5.0 mg/ml w/w PX at 30C; 
enhanced from the value of 3.1 mg/ml for pure PX) and for 4 in 
methanol (9.0 mg/ml PX at 30C) (Figure 13).  The solubility 
curves for 2 methanol and ethanol (see ESI) show less 
pronounced enhancement of solubility, with values (at 30°C) of 
~4.0 and 1.6 mg/ml, respectively.  Thus the solubility of PX in 
these multi-component molecular crystals, in which PX adopts 
its ionised PX form, is enhanced compared with that of the 
parent PX for these solvents. 
For the PX CA complex 10, in contrast, there appears to be a 
reduction in the measured w/w PX solubility in both methanol 
and ethanol (see ESI), also found for the polymorph complex 9 
solubility in methanol.  For these multi-component molecular 
crystals containing PX+ there is thus a reduction in solubility on 
formation of the multi-component material. 
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Figure  13.  Solubility  curves  for  w/w  PX  component  (red)  in  complex  1  in 
methanol (top) and complex 4 in methanol (bottom), compared with the pure PX 
solubility curves (blue). 
Conclusions 
Eight multi-component molecular crystals of PX with NHCs 
have been formed and characterized.  The three poorly basic 
NHCs (pKa = 0.65 - 2.27) resulted in the formation of multi-
component crystals containing the zwitterionic PXZ form (6-8), 
with no intermolecular hydrogen transfer.  All exhibited the 
dimerisation of the PXZ molecules seen in all known 
complexes featuring PXZ, with the strongest hydrogen bond 
donor of the NHC interacting with the enolate oxygen.  In the 
case of PZ and TA this leads to the formation of infinite chains 
due to the symmetry in PZ and the disorder of TA which allow 
the same NH···O¯ and CH···O¯ interactions to form on both 
sides of the molecules.  In the case of BT, discrete hydrogen 
bonded tetramers are formed as the NH donor of BT only lies 
on one side.  The BT:PXZ:PXZ:BT tetramers are analogous to 
the BZZB tetramers formed in the zwitterionic PXZ complexes 
with benzoic acids9.  
Tuning of the pKa values of the co-former allows multi-
component molecular crystals to be formed containing the PX¯ 
anion.  In this way, five complexes were crystallised featuring 
PX¯ by using bases with pKa values in the range 5.33-6.99.  
All PX¯ complexes exhibit consistent hydrogen bonding 
synthons, with interactions of the strongest donors and 
strongest acceptors (NH···O and NH···O¯) prevailing in all 
complexes except 1.  All PX- complexes contain chains with a 
general ABAB arrangement of the molecules. 
The three complexes (1-3) with PX¯:IM+ include a hemihydrate 
as well as 1:1:1 and 4:4:1 ACN solvates.  No non-solvated 
PX¯:IM+ complex could be formed despite varying the 
crystallisation conditions.  Selective crystallisation of the three 
PX¯:IM+ solvates could be controlled by varying the 
crystallisation temperature.   
Analysis of the ΔpKa values for the basic co-formers are in 
general agreement with the ΔpKa rule, but the situation may be 
more complex when PX exists in zwitterionic form.  pKa 
values are generally measured using water as the solvent and in 
cases where zwitterionic forms are present, the transferability to 
different solvents may be less reliable.. 
Multi-component molecular crystals of CA and BA with PX 
resulted in salts where PX is present as a cation (PX+) with both 
the hydroxyl and pyridinium N protonated (9-12).  This is the 
first time PX has been seen in the PX+ form.  Polymorphism of 
the 1:1 CA:PX complex can be induced by changing the 
crystallisation temperature.  Both forms have the same basic 
hydrogen bonding motif linking pairs of PX and CA molecules, 
but the CA¯ molecule in form II is twisted relative to its 
position in form I, forming an extra hydrogen bond to a further 
PX+ molecule rather than dimerising with another CA¯ 
molecule.  A further increase in temperature resulted in the 
production of a 2:1:2 ACN solvate which, perhaps surprisingly, 
reverts back to the motif seen in form I.  . 
Significant solubility enhancements are found for some of the 
multi-component molecular crystals for which this physical 
property has been determined to date, and this is potentially 
significant for the aim of enhancing this physical property in 
multi-component crystals of this, and other, APIs.  However, 
the limited data available to date do not allow for possible 
correlations with PX ionisation states or with crystal packing to 
be drawn out fully; only a limited subset of ionic PX complexes 
have been characterised of which some show significantly 
enhanced solubility in the solvent used compared to pure PX.  
This will be pursued in further work related to the further 
investigation of crystallisation control of molecular complexes 
of APIs and enhancing their physical properties. 
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Table 3.  Summary of Crystallographic Data for 1-6. 
 1 2 3 4 5 6 
Formula 2(C15H12N3O4S), 
2(C3H5N2)+, H2O 
(C15H12N3O4S), 
(C3H5N2)+, 
(C2H3N) 
4(C15H12N3O4S),  
4(C3H5N2)+, 
(C2H3N) 
(C15H12N3O4S), 
 (C4H7N2)+ 
(C15H12N3O4S), 
 (C7H7N2)+ 
2(C15H13N3O4S), 
(C2H3N3) 
M/g mol-1 816.89 440.48 1638.78 413.46 449.48 731.76 
T/K 100 100 100 100 100 100 
Crystal System Triclinic Monoclinic Monoclinic Monoclinic Triclinic Triclinic 
Space Group P‐1 P21/c P21/n P21/n P‐1 P‐1 
a/Å 6.8019(4) 8.1510(5) 6.9103(1) 10.9928(8) 12.005(3) 6.9267(2) 
b/Å 14.4384 (8) 26.5997(17) 22.1444(5) 15.3135(15) 13.789(3) 8.3356(3) 
c/Å 19.8727(12) 10.1579(7) 25.1813(5) 12.551(1) 13.810(4) 28.8177(10) 
α 90.460(2) 90 90 90 72.186(7) 86.485(2) 
β 99.276(2) 113.394(3) 97.068(1) 112.039(4) 68.682(7) 84.209(2) 
γ 101.460(2) 90 90 90 80.962(7) 76.271(1) 
V/Å3 1886.1(2) 2021.3(2) 3824.07(13) 1958.4(3) 2024.8(8) 1606.89(9) 
Z 2 4 2 4 4 2 
ρcal/ g cm-3 1.438 1.447 1.423 1.402 1.474 1.512 
μ/mm-1 0.211 0.202 0.207 0.202 0.202 0.235 
θ Range/° 1.44 ‐ 23.51 1.53 ‐ 29.61 1.63 ‐ 27.08 2.11 ‐ 28.31 1.55 ‐ 23.91 0.71 – 25.00 
Ref. (meas. / ind.) 39251/ 5468 31169/ 5639 55396/ 8406 22181/ 4828 23716/ 6114 35311/ 7358 
Observed>2σ 2890 4386 4565 3085 2700 5437 
Rint 0.1704 0.1084 0.1572 0.1100 0.1716 0.0857 
Completeness % 97.6 99.0 99.9 99.1 97.1 99.9 
Parameters 538 294 592 327 597 503 
GooF 0.949 1.146 0.978 0.985 0.887 1.096 
R1 (obs) 0.0567 0.0601 0.0572 0.0567 0.0618 0.0616 
R1 (all) 0.1543 0.0798 0.1322 0.1021 0.1858 0.0916 
wR2 (all) 0.0996 0.1699 0.1456 0.1309 0.102 0.1327 
ρmax,min/e Å-3 0.334, ‐0.327 0.594, ‐0.594 0.327, ‐0.389 0.519, ‐0.373 0.331, ‐0.339 0.544, ‐0.457 
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Table 4. Summary of crystallographic data for 7-12. 
 7 8 9 10 11 12 
Formula (C15H13N3O4S), 
(C6H5N3) 
2(C15H13N3O4S), 
(C4H4N2) 
(C15H14N3O4S)+, 
(C6HCl2O4) 
(C15H14N3O4S)+, 
(C6HCl2O4) 
(C15H14N3O4S)+, 
 [0.5(C6Cl2O4)], 
(C2H3N) 
(C15H14N3O4S)+, 
(C6HBr2O4) 
M/g mol-1 450.47 742.80 540.32 540.32 476.89 629.24 
T/K 100 100 100 100 100 100 
Crystal System Monoclinic Triclinic Triclinic Monoclinic Triclinic Monoclinic 
Space Group P21/c P‐1 P‐1 P21/c P‐1 P21/c  
a/Å 11.6101(6) 6.792(11) 9.1504(4) 8.5627(5) 7.0616(8) 8.842(2) 
b/Å 26.2908(15) 8.646(15) 10.9678(4) 13.3395(7) 11.6031(13) 13.437(2) 
c/Å 6.7710(3) 29.66(5) 11.7747(5) 19.3963(12) 13.2994(17) 19.242(4) 
α 90 94.159(11) 89.228(2) 90 71.351(5) 90 
β 103.480(3) 90.51(2) 75.765(2) 100.925(3) 84.932(5) 100.518(11) 
γ 90 104.78(4) 70.977(2) 90 78.919(5) 90 
V/Å3 2009.8(2) 1679(5) 1080.00(8) 2175.3(2) 1012.8(2) 2247.8(7) 
Z 4 2 2 4 1 4 
ρcal/ g cm-3 1.489 1.469 1.662 1.650 1.564 1.859 
μ/mm-1 0.205 0.225 0.455 0.452 0.340 3.755 
θ Range/° 1.96 ‐ 20 2.00 ‐ 20 1.79 ‐ 30.56 1.86 ‐ 27.72 1.62 – 22.5 1.86 ‐ 27.83 
Ref. (meas. / ind.) 5992/ 2942 17434/ 6529 30881/ 6607 38649/ 5083 15739/ 2948 62927/ 5308 
Observed>2σ 2320 2898 4819 3284 1959 3937 
Rint 0.0444 0.2110 0.0665 0.0920 0.1007 0.0952 
Completeness % 95.7 95.0 99.8 99.4 98.2 99.4 
Parameters 302 471 376 376 303 333 
GooF 1.081 1.239 0.945 0.922 0.984 0.935 
R1 (obs) 0.0546 0.1739 0.0376 0.0397 0.045 0.0319 
R1 (all) 0.0721 0.2644 0.0586 0.0797 0.0896 0.049 
wR2 (all) 0.1538 0.4876 0.0909 0.0762 0.1065 0.0785 
ρmax,min/e Å-3 0.85, ‐0.365 0.947, ‐0.704 0.524, ‐0.320 0.474, ‐0.458 0.402, ‐0.365 1.092, ‐0.558 
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